Unlike IL-12/23 inhibitors, IL-23 inhibitors only specifically bind to the p19 subunit, preserving the activity of IL-12, which may improve its efficacy in PsA and psoriasis therapy [33–35]. Here, IL37 is linked to psoriasis.